Literature DB >> 25664975

Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys.

Kleber Juvenal Silva Farias1, Paula Renata Lima Machado, José Augusto Pereira Carneiro Muniz, Aline Amaral Imbeloni, Benedito Antônio Lopes da Fonseca.   

Abstract

Dengue virus (DENV) of the Flaviviridae family is a single positive-stranded RNA virus that is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The objective of this study was to investigate the use of chloroquine (CLQ) as an antiviral drug against dengue virus in monkeys. To analyze the action of the drug in vivo, nonhuman primates groups (Aotus azarai infulatus) were inoculated with a subcutaneous injection of a virulent strain of DENV-2, treated and untreated CLQ. Blood hematological, viremia, and serum biochemical values were obtained from 16 DENV-2-inoculated, treated and untreated; four received only CLQ and one mock-infected Aotus monkeys. Monkey serum samples (day 0-10 post-inoculation) were assayed by reverse transcription polymerase chain reaction and Cytometric Bead Array for determination of viremia and inflammatory cytokines, respectively. Additionally, body temperature and activity levels were determined. In the present work, CLQ was effective on replication of DENV-2 in Aotus monkeys; a time viremia reduction was observed compared with the controls. The concentration of tumor necrosis factor alpha and interferon gamma in the serum of the animals had a statistically significant reduction in the groups treated with CLQ after infection compared with the controls. A significant decrease in systemic levels of the liver enzyme aspartate aminotransferase (AST) was also observed in the animals treated with CLQ after infection compared with the controls. These results suggest that CLQ interferes in DENV-2 replication in Aotus monkeys.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25664975      PMCID: PMC4390208          DOI: 10.1089/vim.2014.0090

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  41 in total

1.  Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys.

Authors:  Tadeusz J Kochel; Douglas M Watts; Alfonso S Gozalo; Daniel F Ewing; Kevin R Porter; Kevin L Russell
Journal:  J Infect Dis       Date:  2005-01-31       Impact factor: 5.226

2.  Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.

Authors:  Shashank R Joshi; N Butala; Madhura R Patwardhan; N G Daver; Dhanashree Kelkar
Journal:  J Assoc Physicians India       Date:  2004-07

Review 3.  Structural biology of dengue virus enzymes: towards rational design of therapeutics.

Authors:  Christian G Noble; Pei-Yong Shi
Journal:  Antiviral Res       Date:  2012-09-17       Impact factor: 5.970

4.  Chloroquine inhibits proinflammatory cytokine release into human whole blood.

Authors:  I Karres; J P Kremer; I Dietl; U Steckholzer; M Jochum; W Ertel
Journal:  Am J Physiol       Date:  1998-04

5.  Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.

Authors:  J Velzing; J Groen; M T Drouet; G van Amerongen; C Copra; A D Osterhaus; V Deubel
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

6.  Increased pro-inflammatory cytokines (TNF-alpha and IL-6) and anti-inflammatory compounds (sTNFRp55 and sTNFRp75) in Brazilian patients during exanthematic dengue fever.

Authors:  L M Pinto; S A Oliveira; E L Braga; R M Nogueira; C F Kubelka
Journal:  Mem Inst Oswaldo Cruz       Date:  1999 May-Jun       Impact factor: 2.743

7.  Malariotherapy for HIV patients.

Authors:  H J Heimlich; X P Chen; B Q Xiao; S G Liu; Y H Lu; E G Spletzer; J L Yao
Journal:  Mech Ageing Dev       Date:  1997-02       Impact factor: 5.432

8.  Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections.

Authors:  N J Marchette; S B Halstead; W A Falkler; A Stenhouse; D Nash
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

9.  Immunosuppressive effects of chloroquine: potential effectiveness for treatment of post-transfusion graft-versus-host disease.

Authors:  M Nishimura; N Hidaka; T Akaza; K Tadokoro; T Juji
Journal:  Transfus Med       Date:  1998-09       Impact factor: 2.019

10.  Differing infection patterns of dengue and yellow fever viruses in a human hepatoma cell line.

Authors:  P Marianneau; A M Steffan; C Royer; M T Drouet; A Kirn; V Deubel
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

View more
  24 in total

Review 1.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

Review 2.  Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.

Authors:  Veaceslav Boldescu; Mira A M Behnam; Nikos Vasilakis; Christian D Klein
Journal:  Nat Rev Drug Discov       Date:  2017-05-05       Impact factor: 84.694

3.  Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments.

Authors:  Finny S Varghese; Kai Rausalu; Marika Hakanen; Sirle Saul; Beate M Kümmerer; Petri Susi; Andres Merits; Tero Ahola
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

4.  Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model.

Authors:  Stuart D Dowall; Andrew Bosworth; Robert Watson; Kevin Bewley; Irene Taylor; Emma Rayner; Laura Hunter; Geoff Pearson; Linda Easterbrook; James Pitman; Roger Hewson; Miles W Carroll
Journal:  J Gen Virol       Date:  2015-12       Impact factor: 3.891

Review 5.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.

Authors:  Domenico Plantone; Tatiana Koudriavtseva
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 3.580

Review 6.  Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.

Authors:  Md Abdul Alim Al-Bari
Journal:  Pharmacol Res Perspect       Date:  2017-01-23

Review 7.  The Role of Secretory Autophagy in Zika Virus Transfer through the Placental Barrier.

Authors:  Zhong-Wei Zhang; Zi-Lin Li; Shu Yuan
Journal:  Front Cell Infect Microbiol       Date:  2017-01-09       Impact factor: 5.293

8.  Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.

Authors:  Stanford Schor; Shirit Einav
Journal:  ACS Infect Dis       Date:  2018-01-03       Impact factor: 5.084

9.  Blockade of dengue virus infection and viral cytotoxicity in neuronal cells in vitro and in vivo by targeting endocytic pathways.

Authors:  Min-Ru Ho; Tsung-Ting Tsai; Chia-Ling Chen; Ming-Kai Jhan; Cheng-Chieh Tsai; Yi-Chao Lee; Chun-Han Chen; Chiou-Feng Lin
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

Review 10.  Current Strategies for Inhibition of Chikungunya Infection.

Authors:  Bharat Bhusan Subudhi; Soma Chattopadhyay; Priyadarsee Mishra; Abhishek Kumar
Journal:  Viruses       Date:  2018-05-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.